ALF-5755 is an anti-oxidative and anti-inflammatory protein
ALF-5755 is a recombinant protein derived from the human protein HIP/PAP (Reg3a) known for its anti-oxidative and anti-inflammatory properties. It shares the same properties as the endogenous HIP/PAP.
This molecule is targeted to inflammatory extracellular matrix where it can exert its beneficial effects. Among others, it is involved in the regeneration of pancreatic beta cells, the protection of injured neurons, the protection against liver damages and the protection of the gut microbiota.
How is ALF-5755 addressing insulin resistance?
A local action onmicrobiotafor a systemic benefit
There is mounting evidence that disturbance of the gut microbiota, i.e the bacterial population of our digestive system, (referred to as “dysbiosis”) has consequences not only locally but also on apparently unrelated areas of the body. Indeed, numerous studies have demonstrated the role of the microbiota in the development of chronic inflammatory diseases such as inflammatory diseases of the bowel (IBD) but also metabolic syndrome, type II diabetes, obesity, cardiovascular diseases (Ferreira et al., J. Immunol. Research 2014) or neurological diseases such as Alzheimer’s disease (Kowalski et al., J. Neurogastroenterology and Motility 2019); finally there is now evidence for the impact of the gut microbiota in the development of cancers and their response to therapy (Zitvogel et al., Sci. Trans. Med 2015) and in liver diseases (Brandl et al., Curr. Op. Gastroenterol. 2017)
HIP/PAP has now been shown to profoundly impact, through its antioxydative effect, the overall distribution of gut bacteria by enriching the strictly anaerobic commensal bacteria (Darnaud et al., gastroenterology 2018). HIP/PAP restores patient’s mucosal barrier protection with immunostimulatory properties on the gut barrier function (Waldschmitt N, et al. Gut 2019).; i;e: it reinforces the immune response to various pathogens and counteracts metabolic disorders.
As a derivative of HIP/PAP, the local activity of ALF-5755 on the microbiota is complementary to its systemic mechanism of action on the extracellular matrix. These two convergent mechanisms of action address chronic inflammation and oxydation both involved in various age-related diseases such as type II diabetes, our first indication.
THAC owns the appropriate industrial property for its development with patents on insulin resistance (WO2014/167230), cancer (WO2014/013032) and neuroprotection (WO2010/142800). Acquisition of a fourth patent on microbiota protection is ongoing.